(1 - 11 von 14
)
Hyam I. Levitsky, MD, Joins Antigenics' Board of Directors
www.finanznachrichten.de
Antigenics Inc. (NASDAQ: AGEN) today announced the appointment of Hyam I. Levitsky, MD, to its board of directors. Currently a professor of oncology, …
CellGenesys Reports Positive Results From Phase 2 Trial of GVAX(R)...
www.bionity.com
The trial was conducted at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center by Dr. Hyam Levitsky, professor of Oncology Medicineand Urology, and …
Study Suggests Way to 'Mop Up' Leukemia Cells - Consumer Health ...consumer.healthday.com › leukemia-cancer-news-99
consumer.healthday.com
· ... the ability to get patients off lifelong Gleevec therapy would be a significant advance," Dr. Hyam Levitsky, a professor of oncology, ...
sortiert nach Relevanz / Datum